FDA looks to prepare reviewers for complex submissions
This article was originally published in The Gold Sheet
Executive Summary
The Office of Pharmaceutical Science in FDA's Center for Drug Evaluation and Research is looking to prepare its reviewers for increasingly challenging drug applications as the agency begins to see the submission of novel and complex dosage forms. The office is seeking to find organizations that could deliver a professional development program "to ensure reviewers are current in state-of-the-art pharmaceutical manufacturing and technology," the agency said in a June 2 sources sought notice
You may also be interested in...
Kite Strikes CAR-T Access & Discount Deal For Tecartus In England
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
2020 Sees Sharp Rise In EU New Drug Approvals
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: